Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma

Megan B. Barnet; Robert R. Zielinski; Anne Warby; Craig R. Lewis; Steven Kao

Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma

Megan B. Barnet
, Robert R. Zielinski
, Anne Warby
, Craig R. Lewis
, Steven Kao

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related malignancy with limited treatment options. Immune checkpoint inhibition has demonstrated promising activity in MPM with the use of single-agent pembrolizumab in a mostly chemotherapy-resistant population.1 Here we report significant responses to pembrolizumab after pseudoprogression in two patients with MPM and corresponding patient-reported outcomes (PROs) related to quality of life.

Original language	English
Pages (from-to)	e1-e2
Number of pages	2
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	1
Publication status	Published - Jan 2018

Keywords

asbestos
cancer
immunotherapy
malignant pleural mesothelioma
mesothelioma
quality of life

Cite this

@article{427370bd2d5a4968a57199418ebc683a,

title = "Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma",

abstract = "Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related malignancy with limited treatment options. Immune checkpoint inhibition has demonstrated promising activity in MPM with the use of single-agent pembrolizumab in a mostly chemotherapy-resistant population.1 Here we report significant responses to pembrolizumab after pseudoprogression in two patients with MPM and corresponding patient-reported outcomes (PROs) related to quality of life.",

keywords = "asbestos, cancer, immunotherapy, malignant pleural mesothelioma, mesothelioma, quality of life",

author = "Barnet, \{Megan B.\} and Zielinski, \{Robert R.\} and Anne Warby and Lewis, \{Craig R.\} and Steven Kao",

year = "2018",

month = jan,

language = "English",

volume = "13",

pages = "e1--e2",

journal = "Journal of Thoracic Oncology",

issn = "1556-1380",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma

AU - Barnet, Megan B.

AU - Zielinski, Robert R.

AU - Warby, Anne

AU - Lewis, Craig R.

AU - Kao, Steven

PY - 2018/1

Y1 - 2018/1

N2 - Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related malignancy with limited treatment options. Immune checkpoint inhibition has demonstrated promising activity in MPM with the use of single-agent pembrolizumab in a mostly chemotherapy-resistant population.1 Here we report significant responses to pembrolizumab after pseudoprogression in two patients with MPM and corresponding patient-reported outcomes (PROs) related to quality of life.

AB - Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related malignancy with limited treatment options. Immune checkpoint inhibition has demonstrated promising activity in MPM with the use of single-agent pembrolizumab in a mostly chemotherapy-resistant population.1 Here we report significant responses to pembrolizumab after pseudoprogression in two patients with MPM and corresponding patient-reported outcomes (PROs) related to quality of life.

KW - asbestos

KW - cancer

KW - immunotherapy

KW - malignant pleural mesothelioma

KW - mesothelioma

KW - quality of life

UR - http://hdl.handle.net/1959.7/uws:44426

M3 - Article

C2 - 28919393

SN - 1556-1380

SN - 1556-0864

VL - 13

SP - e1-e2

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 1

ER -

Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma

Abstract

Keywords

Other files and links

Fingerprint

Cite this